NZ731850A - System and method for preventing alopecia - Google Patents

System and method for preventing alopecia

Info

Publication number
NZ731850A
NZ731850A NZ731850A NZ73185015A NZ731850A NZ 731850 A NZ731850 A NZ 731850A NZ 731850 A NZ731850 A NZ 731850A NZ 73185015 A NZ73185015 A NZ 73185015A NZ 731850 A NZ731850 A NZ 731850A
Authority
NZ
New Zealand
Prior art keywords
hair
agonists
alpha
disorders
limitation
Prior art date
Application number
NZ731850A
Other languages
English (en)
Inventor
Ofer A Goren
John Mccoy
Original Assignee
Follea Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Follea Int filed Critical Follea Int
Publication of NZ731850A publication Critical patent/NZ731850A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ731850A 2014-11-14 2015-11-13 System and method for preventing alopecia NZ731850A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462080137P 2014-11-14 2014-11-14
US201562099830P 2015-01-05 2015-01-05
US201562213355P 2015-09-02 2015-09-02
US201562221863P 2015-09-22 2015-09-22
PCT/US2015/060663 WO2016077744A1 (en) 2014-11-14 2015-11-13 System and method for preventing alopecia

Publications (1)

Publication Number Publication Date
NZ731850A true NZ731850A (en) 2023-06-30

Family

ID=55955138

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ731850A NZ731850A (en) 2014-11-14 2015-11-13 System and method for preventing alopecia

Country Status (11)

Country Link
US (2) US10238593B2 (cg-RX-API-DMAC7.html)
EP (1) EP3217967B1 (cg-RX-API-DMAC7.html)
JP (2) JP6829196B2 (cg-RX-API-DMAC7.html)
KR (1) KR102476626B1 (cg-RX-API-DMAC7.html)
CN (1) CN107427479B (cg-RX-API-DMAC7.html)
AU (1) AU2015346126B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017009980A2 (cg-RX-API-DMAC7.html)
CA (1) CA2967375C (cg-RX-API-DMAC7.html)
ES (1) ES2761688T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ731850A (cg-RX-API-DMAC7.html)
WO (1) WO2016077744A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017009980A2 (pt) 2014-11-14 2018-02-14 Follea Int ?sistema e método para prevenção de alopecia?.
WO2016201286A1 (en) 2015-06-11 2016-12-15 Applied Biology, Inc. Treatment of sexual dysfunction
KR102493627B1 (ko) * 2015-11-26 2023-01-31 코웨이 주식회사 호르데닌을 유효성분으로 함유하는 피부암 예방 또는 치료용 약학 조성물
WO2018093370A1 (en) * 2016-11-17 2018-05-24 Follea International System and method for preventing alopecia
EP3426276B1 (en) 2017-05-24 2024-01-24 Follea International Synephrine compositions
WO2019143857A1 (en) * 2018-01-17 2019-07-25 University Of Florida Research Foundation, Incorporated Betel quid cessation therapy with nicotine and pilocarpine
WO2020023084A1 (en) * 2018-07-26 2020-01-30 Applied Biology, Inc. Taar receptor agonists for the treatment of alopecia
CN115135294A (zh) * 2020-02-19 2022-09-30 株式会社资生堂 利用立毛肌细胞激活的老化改善方法
WO2024118094A1 (en) * 2022-11-29 2024-06-06 Follea International System and method for preventing alopecia
CN121190403B (zh) * 2025-09-05 2026-04-07 北京大学第三医院(北京大学第三临床医学院) 一种基于人工智能的雄激素性秃发检测方法及系统

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034109A (en) 1973-01-18 1977-07-05 Wilkinson Sword Limited Compounds having a physiological cooling effect and compositions containing them
US4853216A (en) * 1987-04-02 1989-08-01 Bristol-Myers Company Process and composition for the topical application of alpha1 adrenergic agonist for pilomotor effects
US5055456A (en) * 1989-01-27 1991-10-08 American Cyanamid Co. Anti-alopecia composition
WO1994023748A1 (en) 1993-04-08 1994-10-27 The University Of Queensland Administration of vaso-active agent and therapeutic agent
CA2154979A1 (en) 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US5922341A (en) 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
US6747008B1 (en) * 2000-06-19 2004-06-08 University Of Southern California Methods for treating and preventing alopecia
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
GB0225908D0 (en) 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
US20140011774A1 (en) * 2002-12-05 2014-01-09 University Of Tennessee Research Foundation Selective androgen receptor modulators
US6938624B2 (en) * 2003-01-30 2005-09-06 Hairlocs, Inc. Methods and devices for applying hair extensions
US20060252734A1 (en) 2004-09-08 2006-11-09 Woodward John R Methods of female sexual enhancement
EP1807087A2 (en) 2004-10-12 2007-07-18 Ernir Snorrason Inhibitors of acetylcholinesterase for treating skin diseases
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
PT2656860T (pt) * 2005-06-17 2021-07-28 Wisconsin Alumni Res Found Preparações vasoconstritoras tópicas e métodos para proteção de células durante a quimoterapia e a radioterapia do cancro
US7533676B2 (en) * 2005-07-11 2009-05-19 Aderans Holdings Co., Ltd. Do-it yourself removable/reusable non-chemical highlights and hair extensions
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
US20090068287A1 (en) 2007-09-12 2009-03-12 Susan Welsh Novel topical formulations of flucytosine and uses thereof
PT2818184T (pt) * 2007-11-16 2019-01-28 Aclaris Therapeutics Inc Composições e métodos para o tratamento de púrpura
CN102573848A (zh) 2009-04-24 2012-07-11 济州大学校产学协力团 含有去甲加兰他敏化合物作为活性成分的用于预防和治疗脱发症的组合物
US9084891B2 (en) 2012-02-06 2015-07-21 David Aberizk Pilomotor effect stimulating device and method
JP2016047806A (ja) * 2014-08-28 2016-04-07 一丸ファルコス株式会社 フェニルエチルアミン誘導体又はシネフリン含有アデノシン三リン酸フォスファターゼ発現誘導剤
BR112017009980A2 (pt) 2014-11-14 2018-02-14 Follea Int ?sistema e método para prevenção de alopecia?.
WO2016201286A1 (en) 2015-06-11 2016-12-15 Applied Biology, Inc. Treatment of sexual dysfunction

Also Published As

Publication number Publication date
KR20170098825A (ko) 2017-08-30
US20170333316A1 (en) 2017-11-23
EP3217967A4 (en) 2018-08-15
US10238593B2 (en) 2019-03-26
AU2015346126A1 (en) 2017-06-01
JP6829196B2 (ja) 2021-02-10
CN107427479A (zh) 2017-12-01
HK1247560A1 (zh) 2018-09-28
CA2967375C (en) 2023-08-15
CN107427479B (zh) 2021-03-30
US20170135988A1 (en) 2017-05-18
JP2017533953A (ja) 2017-11-16
ES2761688T3 (es) 2020-05-20
EP3217967B1 (en) 2019-09-18
KR102476626B1 (ko) 2022-12-09
AU2015346126B2 (en) 2020-07-30
BR112017009980A2 (pt) 2018-02-14
CA2967375A1 (en) 2016-05-19
EP3217967A1 (en) 2017-09-20
WO2016077744A1 (en) 2016-05-19
JP7213216B2 (ja) 2023-01-26
JP2021020938A (ja) 2021-02-18

Similar Documents

Publication Publication Date Title
BR112017009980A2 (pt) ?sistema e método para prevenção de alopecia?.
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
MX389228B (es) Composiciones para tratar el cabello.
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
WO2017062835A3 (en) Compositions and methods for treating duchenne muscular dystrophy and related disorders
MX2017010544A (es) Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.
EP4324845A3 (en) Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure
SG10201808661XA (en) Method of treating obesity using antioxidant inflammation modulators
MX2018002344A (es) Metodo para tratar el cancer.
ZA202104737B (en) Methods and compositions for treating skin and hair disorders
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
SA113340494B1 (ar) تركيبة لعلاج اضطرابات أيضية
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
IL304273A (en) Compositions and methods for treating Fabry disease
BR112017019971A2 (pt) exclusão de éxon induzida por anti-sentido em miostatina
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MX2014005404A (es) Composicion cosmetica.
IN2014DE01913A (cg-RX-API-DMAC7.html)
IL279208A (en) Therapeutic methods and compositions for the treatment of pancreatic cancer using 6, 8-bis(benzylsulfenyl)octanoic acid
WO2016168553A8 (en) Deuterated obeticholic acid
SI3348547T1 (sl) Derivati benzimidazola kot zaviralci NAV 1.7 (natrijevi kanalčki, napetostno odvisni, tip IX, podenota alfa (SCN9A)) za zdravljenje bolečine, disurije in multiple skleroze
HK1247136A1 (zh) 包含15-hepe的组合物和其使用方法
MX2025015454A (es) Formulaciones/composiciones que comprenden ibrutinib
MX2019007041A (es) Metodos y composiciones para tratar la enfermedad de parkinson.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2025 BY AJ PARK

Effective date: 20241017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2026 BY AJ PARK

Effective date: 20250917